Galectin Therapeutics Inc
PHPN
Company Profile
Business description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Contact
4960 Peachtree Industrial Boulevard
Suite 240
NorcrossGA30071
USAT: +1 678 620-3186
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,772.00 | 1.00 | -0.01% |
| CAC 40 | 7,639.36 | 26.55 | -0.35% |
| DAX 40 | 23,781.09 | 128.52 | -0.54% |
| Dow JONES (US) | 44,227.90 | 133.13 | 0.30% |
| FTSE 100 | 8,763.60 | 2.64 | 0.03% |
| HKSE | 24,072.28 | 211.87 | -0.87% |
| NASDAQ | 20,311.90 | 57.83 | -0.28% |
| Nikkei 225 | 39,986.33 | 501.06 | -1.24% |
| NZX 50 Index | 12,734.53 | 131.71 | 1.05% |
| S&P 500 | 6,198.92 | 6.03 | -0.10% |
| S&P/ASX 200 | 8,541.10 | 1.20 | -0.01% |
| SSE Composite Index | 3,444.43 | 20.20 | 0.59% |